Changes in local mineral homeostasis facilitate the formation of benign and malignant testicular microcalcifications
Testicular microcalcifications consist of hydroxyapatite and have been associated with an increased risk of testicular germ cell tumors (TGCTs) but are also found in benign cases such as loss-of-function variants in the phosphate transporter SLC34A2 . Here, we show that fibroblast growth factor 23 (FGF23), a regulator of phosphate homeostasis, is expressed in testicular germ cell neoplasia in situ (GCNIS), embryonal carcinoma (EC), and human embryonic stem cells. FGF23 is not glycosylated in TGCTs and therefore cleaved into a C-terminal fragment which competitively antagonizes full-length FGF23. Here, Fgf23 knockout mice presented with marked calcifications in the epididymis, spermatogenic arrest, and focally germ cells expressing the osteoblast marker Osteocalcin (gene name: Bglap , protein name). Moreover, the frequent testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins are associated with lower Slc34a2 and higher Bglap / Slc34a1 (protein name: NPT2a) expression compared with wild-type mice. In accordance, human testicular specimens with microcalcifications also have lower SLC34A2 and a subpopulation of germ cells express phosphate transporter NPT2a, Osteocalcin, and RUNX2 highlighting aberrant local phosphate handling and expression of bone-specific proteins. Mineral disturbance in vitro using calcium or phosphate treatment induced deposition of calcium phosphate in a spermatogonial cell line and this effect was fully rescued by the mineralization inhibitor pyrophosphate. In conclusion, testicular microcalcifications arise secondary to local alterations in mineral homeostasis, which in combination with impaired Sertoli cell function and reduced levels of mineralization inhibitors due to high alkaline phosphatase activity in GCNIS and TGCTs facilitate osteogenic-like differentiation of testicular cells and deposition of hydroxyapatite.
Authors
- Martin Blomberg Jensen (ORCID: https://orcid.org/0000-0003-3800-4253)
- Birgitte Grønkær Toft
- Ida Marie Boisen (ORCID: https://orcid.org/0000-0003-2401-2877)
- Jovana Kaludjerovic
- Anne Jørgensen (ORCID: https://orcid.org/0000-0002-6409-198X)
- Peter J. O’Shaughnessy
- Nadia Krarup Knudsen (ORCID: https://orcid.org/0009-0005-1591-343X)
- Arnela Mehmedbašić
- Lee B. Smith (ORCID: https://orcid.org/0000-0002-4103-3074)
- Anders Juul (ORCID: https://orcid.org/0000-0002-0534-4350)
- Noriko Ide
- Ireen Kooij
- Beate Lanske (ORCID: https://orcid.org/0000-0003-4638-804X)
- Peter W. Andrews (ORCID: https://orcid.org/0000-0001-7215-4410)
- Ewa Rajpert‐De Meyts (ORCID: https://orcid.org/0000-0002-5946-7559)
- Richard Norman (ORCID: https://orcid.org/0000-0002-3112-3893)
- John E. Nielsen
- Mathilde Louise Bagger
Institutions
- University of Copenhagen (DK)
- Dalhousie University (CA)
- Harvard University (US)
- Novo Nordisk Foundation (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- MRC Centre for Reproductive Health (GB)
- The Queen's Medical Research Institute (GB)
- University of Glasgow (GB)
- University of Sheffield (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- eLife
- Published
- 2025-04-25
- DOI
- https://doi.org/10.7554/elife.95545.3
- Citations
- 4
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.72
Funders
- Hørslev-Fonden
- Danish Cancer Society Research Center
- Aase og Ejnar Danielsens Fond
- Novo Nordisk Fonden